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j ourna l homepage: www.e lsev ie r .com/ locate /ygenoEditorialGenomics Special Issue on 5-hydroxymethylationThese are exciting times not only for genomics, but also for
epigenomics, the study of heritable information that is not encoded in
the primary sequence of the DNA itself, but rather in the associated
post-synthetic modiﬁcations to the DNA and to the histones which
package it. With personalised genomics becoming increasingly possible
in the era of the $1000 genome,many are beginning to look at epigenet-
ic contributors to disease. While assessing chromatin alterations is still
relatively expensive to do and difﬁcult to standardise, DNAmethylation
lends itself well to next-generation sequencing techniques and highly-
reproducible results can be obtained from limited patient material.
The study of DNA methylation is one of the oldest branches of epi-
genetics andmethylation is known to be crucial in such diverse process-
es as X-inactivation, imprinting, repeat stability and restriction of selﬁsh
elements. Methylation in mammals is largely present at cytosine in the
form of 5methylcytosine (5mC) and the addition of this mark was long
thought to be an irreversible process which could be removed only by
replicating DNA in the absence of the methyltransferase. Recently this
area has been reinvigorated by the discovery that an oxidised form of
5mC, called 5-hydroxymethylation (5hmC), is relatively abundant in
embryonic stem cells, as well as in the adult brain. 5mC can
be oxidised to 5hmC by the TET family of enzymes (ﬁrst identiﬁed in
leukemias), which may represent the ﬁrst stage in the active removal
of 5mC, or alternativelymay represent a stable epigenetic mark in itself.
In the ﬁrst of the Reviews in this Special Issue dedicated to 5hmC,
Gerd Pfeifer and colleagues present some of the recent ﬁndings in the
area, arguing that 5hmC may be a stable mark in its own right, particu-
larly in the brain, as well as being an intermediate in the active demeth-
ylation of 5mC in the germline and early embryo. Petra Hajkova and
coworkers, in another well-argued piece, review the data suggesting
an important role for TET enzymes and 5hmC in reprogramming, not
only in early life but also for induced pluripotent stem cell production,
suggesting that while there is reasonable support for 5hmC being an
important intermediate in active demethylation, TET-independent
pathways may also exist. Joana Marques and her collaborators concen-
tratemeanwhile on reviewing the sometimes contradictory phenotypes
of the various TET mutations and depletion models that have been gen-
erated, and determining which is favoured by the balance of evidence.
The 5hmC base is found at highest concentrations in the brain, and
Wen and colleagues summarise the patterns of 5hmC distribution
seen over genomic elements such as promoters, enhancers, etc., with
particular emphasis on the patterns seen in brain tissue. In contrast ab-
errant 5hmC distributions are seen in various neurological disorders
such as Alzheimer's and Parkinson's, as reviewed by Xuekun Li andhttp://dx.doi.org/10.1016/j.ygeno.2014.10.007
0888-7543/© 2014 Elsevier Inc. All rights reserved.colleagues. Alterations are also seen in tumour samples, particularly
leukemias. Hall and Ficz review the evidence for alterations to TETs, as
well as to 5hmC levels, being drivers of certain cancer types, calling for
better studies in the area to determine the predictive power of these
changes in cancer.
Better studies require improved techniques, and in the ﬁrst of our
Technology pieces Loring and colleagues describe a streamlined system
for combining one of the most powerful 5hmC detection protocols,
namely TAB-seq, with the popular 450 Kmethylation beadarray system.
This latter platform is alreadywidely used for its reproducibility and low
intrasample variation, so this development is sure to be of interest to
many. One of the main alternative approaches for assaying 5hmC uti-
lises antibodies which bind speciﬁcally to epitopes on the 5hmC mole-
cule. Sun and colleagues outline an improved antibody and method
which allow them to compare 5hmC levels between two cell lines,
even with very limited amounts of starting material. Both approaches
hold great promise for making 5hmC measurements possible in a
broader range of clinical and research samples.
We come full circle back to the early embryo with an intriguing Re-
search article from Jin and colleagues, who show that in mice exposed
daily to enriched environments, alterations in 5hmC levels occur in
the brain, suggesting that early life exposures do indeed leave epigenet-
ic traces. Finally, and on the same theme, a paper from one of our own
labs (Walsh) identiﬁes a class of neuronal genes for which gene body
methylation appears to be important in maintaining transcription
levels. These genes inherit 5mCmethylation from the mother, but con-
vert much of this to 5hmC in the brain where the genes are most highly
transcribed.
We hope these articles will be as enjoyable for you to read as for us,
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